MATERIALS AND METHODS This was a prospective, two arm, comparative study carried
out in patients with locally advanced esophageal carcinoma, attending the Jadao Ba Cancer …

15670 Background: Esophageal carcinoma is one of the most common malignant tumors in
China. The optimal treatment approach for esophageal carcinoma continues to be a matter …

Concurrent chemoradiotherapy is the standard treatment for patients with locally advanced
esophageal squamous cell carcinoma. However, a number of patients present intolerance to …

Purpose/Objective: This Phase I Trial investigates the safety of combining radiation, 5-FU,
and cisplatin with the Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFr TKI) …

PURPOSE: To investigate the feasibility and efficacy of concurrent chemoradiation in
combination with erlotinib for locally advanced esophageal carcinoma. METHODS AND …

This phase I trial investigates the safety of combining radiation, 5-fluorouracil (5-FU) and
cisplatin with the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, in …

4048 Background: The addition of anti-EGFR therapy to chemoradiotherpay in the treatment
of unresectable esophageal squamous cell carcinoma (ESCC) is not well defined, as well as …

Objective To evaluate the safety and efficacy of radiation plus erlotinib in patients with
esophageal cancer older than 70 years. Methods Radiotherapy was prescribed at a daily …

Purpose: Elderly patients with esophageal cancer who are not candidates for
chemoradiation may benefit from targeted agents; hence erlotinib combined with …

Aim: Concurrent chemoradiotherapy is the standard treatment for unresectable esophageal
squamous cell carcinoma (SCC). This phase III trial was designed to determine whether the …